Low allopurinol doses are sufficient to optimize azathioprine therapy in inflammatory bowel disease patients with inadequate thiopurine metabolite concentrations

European Journal of Clinical Pharmacology

Volumn 69, Issue 8, 2013, Pages 1521-1531

  Curkovic, Ivanka ^a   Rentsch, Katharina M ^a   Frei, Pascal ^a   Fried, Michael ^a   Rogler, Gerhard ^a   Kullak Ublick, Gerd A ^a   Jetter, Alexander ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

6 Thioguanine nucleotide; Allopurinol; Azathioprine; Inflammatory bowel diseases; Methylmercaptopurine nucleotide

Indexed keywords

ALANINE AMINOTRANSFERASE; ALLOPURINOL; ASPARTATE AMINOTRANSFERASE; AZATHIOPRINE; BILIRUBIN; MERCAPTOPURINE; THIOGUANOSINE; THIOPURINE METHYLTRANSFERASE;

ADULT; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; ENTERITIS; ENZYME ACTIVITY; FEMALE; FOLLOW UP; HUMAN; LEUKOCYTE COUNT; LOW DRUG DOSE; LYMPHOCYTE COUNT; MALE; NAUSEA; OPTIMAL DRUG DOSE; OUTCOME ASSESSMENT; PATIENT MONITORING; PRIORITY JOURNAL; PROSPECTIVE STUDY;

6-MERCAPTOPURINE; ADULT; AGED; ALLOPURINOL; AZATHIOPRINE; FEMALE; GUANINE NUCLEOTIDES; HUMANS; INFLAMMATORY BOWEL DISEASES; MALE; MIDDLE AGED; THIONUCLEOTIDES;

EID: 84880513630     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-013-1500-1     Document Type: Article

References (30)

1. Dubinsky MC, Lamothe S, Yang HY, Targan SR, Sinnett D, Theoret Y, Seidman EG (2000) Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 118(4):705-713
2. Osterman MT, Kundu R, Lichtenstein GR, Lewis JD (2006) Association of 6-thioguanine nucleotide levels and inflammatory bowel disease activity: a meta-analysis. Gastroenterology 130(4):1047-1053
3. Cuffari C, Theoret Y, Latour S, Seidman G (1996) 6-Mercaptopurine metabolism in Crohn's disease: correlation with efficacy and toxicity. Gut 39(3):401-406
4. Leong RW, Gearry RB, Sparrow MP (2008) Thiopurine hepatotoxicity in inflammatory bowel disease: the role for adding allopurinol. Expert Opin Drug Saf 7(5):607-616. doi: 10.1517/14740338.7.5.607
5. Dubinsky MC, Yang H, Hassard PV, Seidman EG, Kam LY, Abreu MT, Targan SR, Vasiliauskas EA (2002) 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease. Gastroenterology 122(4):904-915
6. Sparrow MP, Hande SA, Friedman S, Lim WC, Reddy SI, Cao D, Hanauer SB (2005) Allopurinol safely and effectively optimizes tioguanine metabolites in inflammatory bowel disease patients not responding to azathioprine and mercaptopurine. Aliment Pharmacol Ther 22(5):441-446
7. Sparrow MP, Hande SA, Friedman S, Cao D, Hanauer SB (2007) Effect of allopurinol on clinical outcomes in inflammatory bowel disease nonresponders to azathioprine or 6-mercaptopurine. Clin Gastroenterol Hepatol 5(2):209-214
8. Ansari A, Elliott T, Baburajan B, Mayhead P, O'Donohue J, Chocair P, Sanderson J, Duley J (2008) Long-term outcome of using allopurinol co-therapy as a strategy for overcoming thiopurine hepatotoxicity in treating inflammatory bowel disease. Aliment Pharmacol Ther 28(6):734-741
9. Ansari A, Patel N, Sanderson J, O'Donohue J, Duley JA, Florin TH (2010) Low-dose azathioprine or mercaptopurine in combination with allopurinol can bypass many adverse drug reactions in patients with inflammatory bowel disease. Aliment Pharmacol Ther 31(6):640-647. doi: 10.1111/j.1365-2036.2009.04221.x
10. Gardiner SJ, Gearry RB, Burt MJ, Chalmers-Watson T, Chapman BA, Ross AG, Stedman CA, Huelsen A, Barclay ML (2011) Allopurinol might improve response to azathioprine and 6-mercaptopurine by correcting an unfavorable metabolite ratio. J Gastroenterol Hepatol 26(1):49-54. doi: 10.1111/j.1440-1746.2010.06489.x
11. Panchal PC, Zielman CJ, Schuhmacher C, Valentine JF (2006) Allopurinol favorably affects AZA/6MP metabolism by lowering 6-MMP levels in patients with hepatoxicity from AZA/6MP without affecting red blood cell thiopurine methyltransferase (TMPT) activity. Gastroenterology 130(4):A660
12. Leung Y, Sparrow MP, Schwartz M, Hanauer SB (2009) Long term efficacy and safety of allopurinol and azathioprine or 6-mercaptopurine in patients with inflammatory bowel disease. J Crohns Colitis 3(3):162-167. doi: 10.1016/j.crohns.2009.02.003
13. Rahhal RM, Bishop WP (2008) Initial clinical experience with allopurinol-thiopurine combination therapy in pediatric inflammatory bowel disease. Inflamm Bowel Dis 14(12):1678-1682. doi: 10.1002/ibd.20522
14. Witte TN, Ginsberg AL (2008) Use of allopurinol with low-dose 6-mercaptopurine in inflammatory bowel disease to achieve optimal active metabolite levels: a review of four cases and the literature. Can J Gastroenterol 22(2):181-185
15. Gerich ME, Quiros JA, Marcin JP, Tennyson L, Henthorn M, Prindiville TP (2010) A prospective evaluation of the impact of allopurinol in pediatric and adult IBD patients with preferential metabolism of 6-mercaptopurine to 6-methylmercaptopurine. J Crohns Colitis 4(5):546-552. doi: 10.1016/j.crohns. 2010.03.004
16. Chocair P, Duley J, Simmonds HA, Cameron JS, Ianhez L, Arap S, Sabbaga E (1993) Low-dose allopurinol plus azathioprine/cyclosporin/prednisolone, a novel immunosuppressive regimen. Lancet 342(8863):83-84
17. Derijks LJ, Gilissen LP, Engels LG, Bos LP, Bus PJ, Lohman JJ, Curvers WL, Van Deventer SJ, Hommes DW, Hooymans PM (2004) Pharmacokinetics of 6-mercaptopurine in patients with inflammatory bowel disease: implications for therapy. Ther Drug Monit 26(3):311-318
18. Sandborn W, Sutherland L, Pearson D, May G, Modigliani R, Prantera C (2000) Azathioprine or 6-mercaptopurine for inducing remission of Crohn's disease. Cochrane Database Syst Rev (2):CD000545
19. Lennard L, Lilleyman JS (1989) Variable mercaptopurine metabolism and treatment outcome in childhood lymphoblastic leukemia. J Clin Oncol 7(12):1816-1823
20. Wusk B, Kullak-Ublick GA, Rammert C, von Eckardstein A, Fried M, Rentsch KM (2004) Thiopurine S-methyltransferase polymorphisms: efficient screening method for patients considering taking thiopurine drugs. Eur J Clin Pharmacol 60(1):5-10. doi: 10.1007/s00228-004-0728-1
21. Wusk B, Kullak-Ublick GA, Rammert C, von Eckardstein A, Fried M, Rentsch KM (2004) Therapeutic drug monitoring of thiopurine drugs in patients with inflammatory bowel disease or autoimmune hepatitis. Eur J Gastroenterol Hepatol 16(12):1407-1413
22. Kröplin T, Weyer N, Gutsche S, Iven H (1998) Thiopurine S-methyltransferase activity in human erythrocytes: a new HPLC method using 6-thioguanine as substrate. Eur J Clin Pharmacol 54(3):265-271
23. Gisbert JP, Linares PM, McNicholl AG, Mate J, Gomollon F (2009) Meta-analysis: the efficacy of azathioprine and mercaptopurine in ulcerative colitis. Aliment Pharmacol Ther 30(2):126-137. doi: 10.1111/j.1365-2036.2009. 04023.x
24. Prefontaine E, Macdonald JK, Sutherland LR (2009) Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease. Cochrane Database Syst Rev (4):CD000545. doi: 10.1002/14651858.CD000545.pub2
25. Govani SM, Higgins PD (2010) Combination of thiopurines and allopurinol: adverse events and clinical benefit in IBD. J Crohns Colitis 4(4):444-449. doi: 10.1016/j.crohns.2010.02.009
26. Cuffari C, Hunt S, Bayless T (2001) Utilisation of erythrocyte 6-thioguanine metabolite levels to optimise azathioprine therapy in patients with inflammatory bowel disease. Gut 48(5):642-646
27. Sandborn WJ, Van OE, Zins BJ, Tremaine WJ, Mays DC, Lipsky JJ (1995) An intravenous loading dose of azathioprine decreases the time to response in patients with Crohn's disease. Gastroenterology 109(6):1808-1817
28. Lennard L, Harrington CI, Wood M, Maddocks JL (1987) Metabolism of azathioprine to 6-thioguanine nucleotides in patients with pemphigus vulgaris. Br J Clin Pharmacol 23(2):229-233
29. Szumlanski CL, Weinshilboum RM (1995) Sulphasalazine inhibition of thiopurine methyltransferase: possible mechanism for interaction with 6-mercaptopurine and azathioprine. Br J Clin Pharmacol 39(4):456-459
30. Al Rifai A, Prasad N, Shuttleworth E, McBurney H, Pushpakom S, Robinson A, Newman W, Campbell S (2011) Natural history of azathioprine-associated lymphopenia in inflammatory bowel disease patients: a prospective observational study. Eur J Gastroenterol Hepatol 23(2):153-158. doi: 10.1097/MEG. 0b013e32834233a2